Administration of a soluble activin type IIB receptor promotes skeletal muscle growth independent of fiber type

Samuel M. Cadena, Kathleen N. Tomkinson, Travis E. Monnell, Matthew S. Spaits, Ravindra Kumar, Kathryn W. Underwood, R. Scott Pearsall, and Jennifer L. Lachey

Submitted 5 August 2009; accepted in final form 6 May 2010

Cadena SM, Tomkinson KN, Monnell TE, Spaits MS, Kumar R, Underwood KW, Pearsall RS, Lachey JL. Administration of a soluble activin type IIB receptor promotes skeletal muscle growth independent of fiber type. J Appl Physiol 109: 635–642, 2010. First published May 13, 2010; doi:10.1152/japplphysiol.00866.2009.—This is the first report that inhibition of negative regulators of skeletal muscle by a soluble form of activin type IIB receptor (ACE-031) increases muscle mass independent of fiber-type expression. This finding is distinct from the effects of selective pharmacological inhibition of myostatin (GDF-8), which predominantly targets type II fibers. In our study 8-wk-old C57BL/6 mice were treated with ACE-031 or vehicle control for 28 days. By the end of treatment, mean body weight of the ACE-031 group was 16% greater than that of the control group, and wet weights of soleus, plantaris, gastrocnemius, and extensor digitorum longus muscles increased by 33, 44, 46 and 26%, respectively ($P < 0.05$). Soleus fiber-type distribution was unchanged with ACE-031 administration, and mean fiber cross-sectional area increased by 22 and 28% ($P < 0.05$) in type I and II fibers, respectively. In the plantaris, a predominantly type II fiber muscle, mean fiber cross-sectional area increased by 57% with ACE-031 treatment. Analysis of myosin heavy chain (MHC) isoform transcripts by real-time PCR indicated no change in transcript levels in the soleus, but a decline in MHC I and IIa in the plantaris. In contrast, electrophoretic separation of total soleus and plantaris protein indicated that there was no change in the proportion of MHC isoforms in either muscle. Thus these data provide optimism that ACE-031 may be a viable therapeutic in the treatment of musculoskeletal diseases. Future studies should be undertaken to confirm that the observed effects are not age dependent or due to the relatively short study duration.

myostatin; GDF-8; myosin heavy chain; muscular dystrophy

GENETIC DISORDERS TARGETING skeletal muscle are associated with muscle loss, weakness, disability, and mortality (14, 22). While advances in gene therapies may ultimately allow these inherited diseases to be treated directly, therapeutics that effectively promote skeletal muscle growth may help to improve quality of life and reduce mortality of those who are afflicted with these disorders. In this light, the modulation of myostatin (GDF-8) function in adult skeletal muscle is an important stratagem in the treatment of muscle wasting in chronic disease. Naturally occurring mutations in the myostatin gene, resulting in deficiencies in the mature myostatin protein, are associated with a hypermuscular phenotype in species ranging from sheep to humans (10, 29, 32, 38). Targeted disruption of the myostatin gene in mice is associated with a 200–300% increase in muscle size that is characterized as both hypertrophic and hyperplastic (28). When investigated in mouse models of muscle degeneration, such as muscular dystrophy (43) or acute muscle injury (40, 42), myostatin deficiency has been shown to stimulate growth of both dystrophic and injured muscles and is associated with greater muscle mass, improved morphology, and reduced fibrosis.

The discovery of biological inhibitors of myostatin, such as follistatin (4), follistatin-related gene (19), GDF-associated serum protein-1 (15), and the myostatin propeptide (19), has offered a multifaceted approach to the treatment of muscular degenerative diseases through the neutralization of myostatin. Exploiting these naturally occurring inhibitors or their derivatives by means of overexpression (33, 35) or gene delivery (15) has produced substantial improvements in muscle mass and function in both normal and dystrophic muscle that is not unlike that seen in myostatin null mice. Similarly, the myostatin neutralizing antibody JA16 administered to mdx mice, a mouse model of Duchenne muscular dystrophy, markedly increased muscle mass and absolute force production of dystrophic muscles, thus improving functional capacity so that dystrophic mice treated with JA16 performed similarly to wild-type controls in an endurance test (8).

It has been proposed that the regulation of skeletal muscle is not the sole responsibility of myostatin, but is shared by other members of the transforming growth factor-β superfamily. For instance, ectopic expression of activin A inhibits myoblast differentiation and the expression of creatine phosphokinase, a surrogate marker of myotube maturation (27). Similarly, bone morphogenetic protein-2 and -7 are correlated with a decline in protein synthesis in developing skeletal muscle (39). Although the role of these factors has not been characterized in adult skeletal muscle, there is evidence that at least one other transforming growth factor-β family member functions as a negative regulator of skeletal muscle mass postnatally. Administration of a soluble form of the activin type IIB receptor (ActRIIB) has been shown to increase muscle mass to a greater extent than that of a myostatin-specific neutralizing antibody (26). Furthermore, administration of soluble ActRIIB to hypermuscular myostatin-deficient mice produces further increases in skeletal muscle mass (26). Therefore, the use of an agent that targets multiple negative regulators of skeletal muscle may prove more effective in stimulating muscle growth in those afflicted by diseases associated with muscle loss and degeneration.

The contractile (slow vs. fast) and metabolic (oxidative vs. glycolytic) properties of any given muscle are largely the consequence of the combined expression of various myosin heavy chain (MHC) isoforms. The MHC isoforms predominantly expressed in adult rodent skeletal muscle, in the order of their slow/oxidative to fast/glycolytic phenotype, are I, IIA, IIX,
and Iib. While myostatin deficiency in mice does not alter the amount of MHC expressed per milligram of total protein (45), it is associated with an increase in MHC Iib expression at the expense of MHC I (13, 18), resulting in muscles that are more susceptible to fatigue (18). Similarly, cattle deficient in myostatin are characterized by decreased endurance capacity and a higher glycolytic profile at the whole body level (20), presenting with significantly greater blood lactate levels during forced exercise. Slow-twitch oxidative fibers are important in insulin-mediated glucose uptake in skeletal muscle (7), and low type I fiber expression is associated with type 2 diabetes (34) and has been identified as a predictor of obesity and cardiovascular disease (21). Thus a shift in a MHC profile that is associated with a faster more glycolytic phenotype may be an undesirable consequence of myostatin-specific inhibition, regardless of its muscle-building potential.

The shift in MHC isoform expression associated with myostatin deficiency is largely a developmental phenomenon, as this phenotype is not recapitulated in adult mice administered a myostatin-neutralizing antibody (13). However, to date, it is not known whether inhibiting multiple regulators of skeletal muscle will result in a change in the inherent MHC profile. Therefore, the purpose of the present study was to investigate the effects of ACE-031, a soluble form of the extracellular domain of ActRIIB fused to the Fc portion of human IgG, on skeletal muscle mass, fiber-type distribution, and MHC isoform expression in mice.

MATERIALS AND METHODS

Expression and purification of ACE-031. The ActRIIB extracellular domain was produced by PCR amplification of the human ActRIIB gene. The primers used for the 5’ and 3’ end included a SfoI and AgeI restriction site, respectively. The PCR product was purified, digested with SfoI and AgeI, and ligated to the pAID4 hFc vector (containing the tissue plasminogen activator signal sequence) to create the pAID4 ActRIIB.hFc expression construct. The sequences of ActRIIB extracellular domain and human immunoglobulin Fc region were confirmed by double-strand dideoxy sequencing. ActRIIB.hFc plasmid expressing ActRIIB.hFc was isolated. ActRIIB.hFc was purified from Tris-buffered saline (TBS; 10 mM Tris, 137 mM NaCl, and 2.7 mM KCl) protein wash 1 (300 mM NaCl) protein wash 2 (100 mM NaCl, 0.1% SDS, and 2.5% tritybutylphosphate). Protein was solubilized in 1% SDS and 2.5% tritybutylphosphate. MHC isoforms were separated according to the method described by Fauteck and Kandarian (12). Briefly, the stacking and separating gels consisted of 4% acrylamide agarose gel. The separating gel was run at 7.5% and the stacking gel was run at 4%, with a 4-mm-wide well. The gels were stained with Coomassie blue and visualized with the Thermo Scientific, Wilmington, DE). total RNA (100 ng) was converted to cDNA by the Moloney murine leukemia virus reverse transcriptase in the presence of random hexamers, dNTP mixture, and RNase inhibitor (Taqman Reverse Transcription Reagents, Applied Biosystems, Foster City, CA). First-strand cDNAs were amplified, and cDNA levels were quantified by real-time PCR using custom and predesigned forward and reverse primers and a fluorogenic Taqman probe (Applied Biosystems). Custom probe/primer sets for MHC I, Ila, and Iib were designed using Primer Express version 1.5 (Applied Biosystems) and synthesized by Applied Biosystems. Custom primer and probe sequences were as follows: 5’-CCA AGA GCC GGG ACA TTG-3’ (forward), 5’T-TTG GAG CTG GGT AGC ACA AGA-3’ (reverse), and 5’T-GGC AAA GGG CCT GAA-3’ (probe) for MHC IIa; 5’-GGT TGC GCA AAC AGG AGA GA-3’ (forward), 5’-CCA AAT CCT GAA GCC GCA AAA ACT-3’ (reverse), and 5’-ACT TAC CAG ACA GAA GAA-3’ (probe) for MHC Ila; and 5’-AAC AGA AGC GCA ACA TCG AA-3’ (forward), 5’T-CTT AGT CTG TTG TGC CAC CAA GTC-3’ (reverse), and 5’-ACC TAC CAG ACC GAG-3’ (probe) for MHC Iib. The Taqman predesigned probe/primer set for MHC Ix (MYH1; Mm01332489_m1), was purchased from Applied Biosystems. All probes were labeled with FAM at the 5’-end, carried the MGB quencher at the 3’-end, and were complementary to an exon/exon junction so as to avoid the amplification of residual genomic DNA. cDNA levels were normalized to 18S levels in multiplex reactions. Amplifications were performed in a 7300 Real-Time PCR System (Applied Biosystems).

MHC isoform separation. Protein was isolated according to the TRI Reagent method. Briefly, the organic/phenol phase separated from the RNA isolation procedure was mixed with 100% ethanol and centrifuged to pellet and remove DNA. Three volumes of acetone were then added to precipitate protein. The protein precipitate was pelleted by centrifugation and was washed three times in protein wash 1 (300 mM guanidine hydrochloride in 95% ethanol and 2.5% glycerol) and once in protein wash 2 (95% ethanol, 2.5% glycerol). Protein was solubilized in 1% SDS and 2.5% tritybutylphosphate. MHC isoforms were separated according to the method described by Fauteck and Kandarian (12). Briefly, the stacking and separating gels consisted of 30% glycerol and 3.5% and 7% acrylamide, respectively. Electrophoresis was performed using a constant voltage of 70 V for 24 h at 4°C. Gels were stained with Coomassie blue and visualized with the Chemi Genius Bio Imaging System (Syngene, Cambridge, UK) and GeneSnap 7.04 software (Syngene). Densitometric analysis was performed with GeneTools 3.07 software (Syngene). MHC Iia and Ibx...
isofoms migrated closely together, appearing as a single band, and were, therefore, not possible to quantify separately.

Statistical analysis. Data are reported as means ± SE. Nonnormally distributed variables were log-transformed so that data were normally distributed before statistical analysis. Body weight was evaluated by a two-way ANOVA to measure main effects of the time and ACE-031 treatment variables, as well as their interaction. Analysis of body weight included only the first 25 days of the experimental period as terminal body weights were not collected. Muscle weights and MHC protein and transcript levels were analyzed by a nonpaired Student's t-test. Muscle-specific differences were analyzed by ANOVA followed by a Bonferroni adjustment for multiple comparisons. Differences were considered statistically significant when the two-tailed P-value was ≤0.05. Analysis of variance measurements were performed with SAS 9.1 for Windows (SAS Institute, Cary, NC).

RESULTS

ACE-031 increases body and muscle weight. We used body weight measurements throughout the experimental period as a longitudinal corroborative marker of skeletal muscle mass. Both ACE-031- and vehicle-treated mice presented with a substantial increase in body weight by day 25 of the experiment (terminal body weights were not collected). However, as shown in Fig. 1, mice treated with ACE-031 exhibited a sharper rate of growth throughout and gained ∼16% more body weight than vehicle-treated controls. We found significant main effects for ACE-031 treatment and time (P < 0.05 and P < 0.01, respectively). We also detected a significant treatment × time interaction, indicating the rate of growth, or slope of the line, was significantly greater in the ACE-031-treated group (P < 0.01).

At the end of the study, lower hindlimb skeletal muscles were harvested on the basis of their function and fiber-type distribution. We selected the soleus, plantaris, and gastrocnemius, which function in plantar flexion, and their antagonist, the EDL, a dorsiflexor. The soleus is relatively rich in type I fibers; however, this varies largely between strains. For instance, the proportion of type I fibers in the mouse soleus ranges from 35% in C57BL/6 mice to 75% in CBA mice. On the other hand, gastrocnemius (17), plantaris (16), and EDL (3) contain values that are significantly different from each other, P < 0.05.

Insoleus type I and II fiber mean cross-sectional areas suggests the ACE-031-treated mice (P < 0.01; Fig. 2), respectively. A comparable gain in weights among plantar flexors indicates that ACE-031 does not discriminate between muscles on the basis of fiber-type distribution. On the other hand, the degree of weight gain in the EDL was significantly less than that of the EDL. Muscle weights are presented as means ± SE (A–C) and percent differences ± SE for percent differences (E). *P < 0.05; **P < 0.01. Bars annotated with the same letter contain values that are significantly different from each other, P < 0.05.

ACE-031 administration, and both fiber types exhibited a comparable increase in muscle weight; however, the percent difference in plantaris weight was significantly greater than that of the EDL. Muscle weights exceeded that of the vehicle-treated controls, such that ACE-031-treated mice gained 16% more body weight by day 25 of the experimental period. Values are presented as means ± SE. Body weight was evaluated by a two-way ANOVA; there was a significant main effect for ACE-031 treatment (P < 0.05), time (P < 0.01), and treatment × time interaction (P < 0.01). TBS, Tris-buffered saline.

ACE-031-induced muscle gain is the result of both type I and type II fiber hypertrophy. Next we performed a morphometric analysis of the type-I-rich soleus and type-II-rich plantaris to determine whether ACE-031-induced muscle growth was fiber-type specific. Soleus muscle fibers were stained for fast MHC expression and with wheat germ agglutinin to examine fiber-type distribution and cross-sectional areas (Fig. 3). At the end of the experimental period, morphometric analysis of the soleus revealed no change in the total number of fibers in response to ACE-031 administration (Fig. 4C and Table 1). Upon staining for fast MHC expression, we did not detect a change in the distribution of type I or II fibers with ACE-031 administration, and both fiber types exhibited a rightward shift in their respective cross-sectional area frequency distribution plots (Fig. 4, A and B). Mean cross-sectional area of type I and II fibers of the soleus increased by 22 and 29% in the ACE-031-treated group, respectively (P < 0.05; Fig. 4, A and B, insets, and Table 1). A similar increase in soleus type I and II fiber mean cross-sectional areas suggests

![Fig. 1.](http://jap.physiology.org/)
that the action of ACE-031 is not preferential to either fiber type.

In both the TBS- and ACE-031-treated groups, the plantaris consisted almost exclusively of type II fibers (Fig. 5). Due to the paucity of type I fibers, results for type I and II fibers of the plantaris were combined. There was no difference in total fiber number between ACE-031- and TBS-treated mice (Fig. 6 and Table 1). On the other hand, ACE-031 administration was associated with a rightward shift in the plantaris fiber cross-sectional area frequency distribution plot, so that mean fiber cross-sectional area was 57% greater than that of the TBS-treated group (*P* < 0.01; Fig. 6A and Table 1).

ACE-031 does not alter the proportion of MHC isoform proteins. We utilized real-time PCR to determine whether the expression of MHC isoforms differed at the level of transcription in response to 28 days of ACE-031 administration. As shown in Fig. 7A, soleus muscles presented with a similar pattern of MHC isoform transcript expression in ACE-031- and TBS-treated mice. MHC I transcripts were most abundant followed by IIa, IIX, and IIb. In contrast, MHC IIX and IIb transcripts were greatest in the plantaris of both ACE-031- and TBS-treated mice, followed by IIa and I. The plantaris exhibited a significant decline in MHC I and IIa transcript levels (*P* < 0.05) with ACE-031 administration, but no change was observed in the expression of IIX and IIb transcripts (*P* > 0.05; Fig. 7B).

We isolated total protein from the soleus and plantaris to determine whether protein expression of MHC isoforms followed a similar pattern of expression as their corresponding transcripts. In rodent skeletal muscle, electrophoretic separation of MHC isoforms is typically characterized by a rapid migration of MHC I followed by IIb, IIX, and IIa (12). In our experiment, MHC isoforms followed a similar pattern of migration (Fig. 8A); however, MHC IIa and IIX migrated closely together, appearing as a single band, and were, therefore, difficult to quantify separately. From here on they are referred to as MHC IIa/IIX.

Soleus MHC content in the TBS-treated mice was 37% type I, 57% IIa/IIX, and 6% IIb (Fig. 8B). These levels were not different after 28 days of ACE-031 administration (34%, I; 61% IIa/I; 5% IIb). In the plantaris of the TBS-treated group, only MHC IIa/IIX and IIb were detected at 35 and 65%, respectively. These levels did not differ significantly with ACE-031 administration (30% type IIa/I; 70% type IIb; Fig. 8C).

Thus the decline in MHC I and IIa transcripts was not associated with a corresponding decrease in MHC isoform protein levels within the 28-day period of treatment; however, as we were unable to distinguish between MHC IIa and IIX, we could not determine whether there was a change in the expression of the individual isoforms. Additionally, the duration of treatment may not have been sufficient to alter the MHC profile at the protein level.

**DISCUSSION**

The hypermuscular phenotype associated with the numerous species presenting with myostatin null mutations has encour-
aged the development of myostatin antagonists that offer promising new therapies in the prevention of muscle loss and function associated with musculoskeletal disorders. Preclinical studies investigating myostatin inhibition in a mouse model of muscular dystrophy have demonstrated significant improvements in both muscle mass and functional capacity (8, 9). Interestingly, the use of a myostatin neutralizing antibody in a clinical trial consisting of muscular dystrophy patients failed to yield similar results (41). Although the neutralizing antibody was associated with improvements in contractile properties at the single fiber level (24), this did not translate to greater muscle mass or functional capacity at the whole body level. Therefore, employing a more broad-based therapeutic, i.e., one that inhibits multiple negative regulators of skeletal muscle, may be necessary to augment the efficacy of these therapies.

To date, several preclinical studies have been completed investigating the effects of RAP-031, an analog of ACE-031 containing the Fc region of murine IgG. These studies have demonstrated improvements in obesity and insulin sensitivity (2), as well as increases in muscle mass and functional capacity in mouse models of hypoxia (36) and amyotrophic lateral sclerosis (31). Consistent with RAP-031, we have shown that muscle mass is increased by the administration of ACE-031, a soluble form of the extracellular region of ActRIIB fused to the Fc region of human IgG. Furthermore, we have also shown that muscle growth occurs in a non-fiber-type-specific manner, without altering fiber-type distribution or the MHC profile after 28 days of treatment.

Consistent with results reported from previous myostatin blockade experiments (8, 47), ACE-031 administration produced a significant increase in body weight that corroborated an increase in muscle mass. Administration of the myostatin neutralizing antibody JA16 for 15 wk produced a significant increase in body weight compared with nontreated controls (47). However, in our experiment, the administration of ACE-031 for only 4 wk also produced a significant increase in body weight (Fig. 1). We suspect that the more rapid degree of weight gain is attributed largely to the greater muscle-building capacity of ACE-031 via its ability to inhibit multiple ActRIIB ligands functioning as negative regulators of skeletal muscle. This may indeed be the case, as muscles exhibited a pattern of growth that was proportionately greater than that of body weight (Fig. 2, C and E). Our work is consistent with Lee (25), who observed similar increases in muscle weights after 4 wk of treatment with soluble ActRIIB. Furthermore, a side-by-side

### Table 1. Soleus and plantaris fiber cross-sectional area and total fiber number

<table>
<thead>
<tr>
<th></th>
<th>Soleus</th>
<th>Plantaris Type I and II Combined</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Fiber cross-sectional area, μm²</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TBS</td>
<td>1,365.61 ± 116.83</td>
<td>1,101.39 ± 71.78</td>
</tr>
<tr>
<td>ACE-031</td>
<td>1,747.49 ± 43.05*</td>
<td>1,557.52 ± 70.36†</td>
</tr>
<tr>
<td><strong>Total fiber number</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TBS</td>
<td>311.80 ± 35.84</td>
<td>766.20 ± 123.98</td>
</tr>
<tr>
<td>ACE-031</td>
<td>290.60 ± 10.68</td>
<td>650.40 ± 25.48</td>
</tr>
</tbody>
</table>

Values are means ± SE. TBS, Tris-buffered saline. *P < 0.05, †P < 0.001: TBS vs. ACE-031.

![Fig. 5](image1.png)

**Fig. 5.** Representative cross section of plantaris. Cross sections of plantaris muscles from mice treated with TBS (A and C) or ACE-031 (B and D) and stained for fast MHC (A and B) or outlined with wheat germ agglutinin (C and D) are shown. Scale bar: 50 μm.

![Fig. 6](image2.png)

**Fig. 6.** Treatment with ACE-031 promotes hypertrophy but not hyperplasia in plantaris fibers. A: plantaris fiber cross-sectional area frequency distribution shifts to the right with ACE-031 treatment and is associated with an increase in mean cross-sectional area (inset). B: there was no change in the total number of fibers with ACE-031 administration. Values in A inset and B are presented as means ± SE. **P < 0.01.
comparison of the myostatin-neutralizing antibody JA16 and soluble ActRIIB in myostatin-deficient mice concluded that the inhibition of multiple ActRIIB ligands stimulates greater muscle growth than myostatin inhibition alone (26).

We have also demonstrated that ACE-031-induced muscle growth does not discriminate on the basis of fiber-type distribution. We observed comparable increases in the weights of the type I-rich soleus and the type II-rich plantaris and gastrocnemius (Fig. 2, A–C and E). To our knowledge, there are no reports specifically investigating the effects of myostatin inhibition on muscles that differ in fiber-type distribution or MHC isoform content. Therefore, we are the first to report that the inhibition of myostatin and other negative regulators of skeletal muscle by a soluble form of ActRIIB increases muscle mass, independent of fiber-type expression. Interestingly, we observed a significant difference in weight gain between the plantaris and EDL; muscles that differ on the basis of function, but not fiber-type expression. As a plantar flexor, the plantaris bears considerably more body weight than the EDL, which functions in dorsiflexion and metatarsal extension and, consequently, is limited to only bearing the weight of the foot. Therefore, muscle function and the degree of weight-bearing may be influential in establishing the degree of muscle growth in response to the inhibition of negative regulators of skeletal muscle. One may argue that, as the soleus is relatively more active during normal weight-bearing (44), this muscle would be most responsive to ACE-031 treatment. However, according to Mendias et al. (30), ActRIIB expression in the soleus is only 50% of that of the EDL, thereby rendering the soleus less responsive to ActRIIB loss of signaling. On the other hand, if muscle growth is indeed proportional to activity level, this may compensate for lower ActRIIB expression, ultimately leading to a net gain of muscle. However, to better clarify the role of weight-bearing and muscle function on the degree of ACE-031-induced muscle growth, future studies should investigate the effects of ACE-031 on muscles with diminished activity or function, such as those subjected to unloading or immobilization.

Girgenrath et al. (13) reported that 12 wk of myostatin inhibition by a neutralizing antibody did not alter fiber-type distribution or MHC isoform transcript levels. Consistent with this, we did not observe a difference in fiber-type distribution of the soleus or plantaris of ACE-031- and TBS-treated mice after 4 wk of treatment (Fig. 4C and data not shown). Moreover, the hypertrophic response to ACE-031 was not fiber-type specific, as type I and II fibers of the soleus exhibited a comparable increase in cross-sectional area (Fig. 4, A and B). While we did not detect a difference in the proportion of MHC isoforms in the soleus or plantaris after 28 days of ACE-031 treatment (Fig. 8), we did detect a decline in MHC I and IIA transcript levels in the plantaris (Fig. 7B), suggesting the duration of treatment was not adequate to stimulate changes at the protein level. However, as the half-life of MHC proteins is ~7–10 days (6), we believe that 28 days of ACE-031 treatment is sufficient to detect a shift in MHC isoform protein levels.
levels. For example, a decline in type I and IIA fibers and an increase in type IIX and IIB fibers is detected after 4 wk of \( \beta_2 \)-adrenoceptor agonist administration (5, 37), and changes in MHC profile are observed in as little as 2 wk of hindlimb unloading (11) and compensatory hypertrophy (1) in rats. Therefore, we believe it is unlikely that ACE-031 administration induces changes in fiber-type distribution in skeletal muscle. However, this should be confirmed in future studies involving a longer duration of treatment in mice and other species. Last, myostatin deficiency is associated with a decrease in myocyte enhance factor 2 expression and an increase in MyoD (18); a pattern of myogenic regulatory factor (MRF) expression indicative of a faster and more glycogenic phenotype (23, 46). While we did not measure MRF expression in the present study, future studies should address the role of MRFs in ACE-031-induced hypertrophy and their potential consequences on the inherent MHC profile.

In summary, the inhibition of myostatin and other negative regulators of skeletal muscle by ACE-031 may offer promise as a potential therapy in the treatment of diseases affecting skeletal muscle, such as muscular dystrophy and amyotrophic lateral sclerosis. An advantage of this treatment over other prospective treatments, such as \( \beta_2 \)-adrenoceptor agonists, is that it stimulates muscle growth in a non-fiber-type-specific manner, without altering the MHC chain profile or fiber-type distribution.

ACKNOWLEDGMENTS

We thank Edouard Vannier (Tufts Medical Center, Boston, MA) for designing custom MHC I, IIA, and IIB probe and primer sequences; Yijun Yang (Acceleron Pharma) for assistance with statistical analysis; and Tim Ahern for help editing this paper.

DISCLOSURES

The authors declare competing financial interests as experiments were conceived, designed, performed, and analyzed by full-time Acceleron Pharma employees.

REFERENCES


